Industry Roundtable Discussion: Process Development for Complex Biologics: Bispecifics, Fusion Proteins and Antibody-Drug Conjugates
- Addressing mispairing, aggregation, low titres and other molecule-specific challenges
- Adapting established upstream process platforms for complex biologic formats
- Integrating developability assessment and early process optimisation to improve manufacturability